Additional therapeutic application of 15-PGDH inhibitors including in models of graft versus host disease, bone marrow failure disorders, and other heme malignancies. Identification of novel cell ...

Cellectis SA's pipeline consists of allogeneic CAR T-cell therapies that have the potential to make meaningful dents in heme malignancies. The financial picture remains strong, bolstered further ...

Curis' pipeline includes three drugs focused on Heme Malignancies and three on Immune Checkpoint Inhibitors, with updates on their two primary programs expected in 2024. Curis (NASDAQ:CRIS ...

WALTHAM, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR ...

Company to present poster on initial data from heme malignancies Phase 1 trial at the 65 th ASH Annual Meeting and Exposition; Company to host virtual KOL event on Monday, December 11, 2023 ...

Heme Malignancies Program: TScan’s two lead TCR-T therapy candidates, TSC-100 and TSC-101, are designed to treat residual disease and prevent relapse in patients with acute myeloid leukemia (AML ...